17-hydroxyprogesterone blunts the hypertensive response associated with reductions in uterine perfusion pressure in pregnant rats

American Journal of Obstetrics and Gynecology

Volumn 201, Issue 3, 2009, Pages 324.e1-324.e6

  Veillon Jr , Edward W ^a   Keiser, Sharon D ^a   Parrish, Marc R ^a   Bennett, William ^a   Cockrell, Kathy ^a   Ray, Lillian F ^a   Granger, Joey P ^a   Martin Jr , James N ^a   LaMarca, Babbette ^a  

^a Division of Maternal Fetal Medicine   (United States)

Author keywords

17 hydroxyprogesterone caproate; endothelin; hypertension; preeclampsia; reduced uterine perfusion

Indexed keywords

ENDOTHELIN 1; GENOMIC DNA; HYDROXYPROGESTERONE CAPROATE; INTERLEUKIN 6; MESSENGER RNA; PROGESTERONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; DRUG DOSE INCREASE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS; MATERNAL HYPERTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOGENESIS; PERFUSION PRESSURE; PLACENTA INSUFFICIENCY; PLACENTA PERFUSION; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TISSUE LEVEL;

EID: 69349095893     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.05.054     Document Type: Article

References (22)

1. Dodd J.M., Flenady V., Cincotta R., and Crowther C.A. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev (2006) CD004947
2. da Fonseca E.B., Bittar R.E., Carvalho M.H., and Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 188 (2003) 419-424
3. Meis P.J., Klebanoff M., Thom E., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 348 (2003) 2379-2385
4. Salas S.P., Marshall G., Gutiérrez B.L., and Rosso P. Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension 47 (2006) 203-208
5. Sammour M.B., El-Kabarity H., Fawzy M.M., and Schindler A.E. Prevention and treatment of pregnancy-induced hypertension (preeclampsia) with progestogens. J Steroid Biochem Mol Biol 97 (2005) 439-440
6. Kristiansson P., and Wang J.X. Reproductive hormones and blood pressure during pregnancy. Hum Reprod 16 (2001) 13-17
7. Ragab M.I., Sammour H., El-Kabarity H., and Hegazi R. Progesterone a treatment for pre-eclamptic toxaemia. Ain-Shams Med J 22 (1971) 9-24
8. American College of Obstetricians and Gynecologists. Diagnosis and management of preeclampsia and eclampsia. ACOG practice bulletin no. 33. Obstet Gynecol 99 (2002) 159-167
9. Alexander B.T., Kassab S.E., Miller M.T., et al. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 37 (2001) 1191-1195
10. Nienartowicz A., Link S., and Moll W. Adaptation of the uterine arcade in rats during pregnancy. J Develop Physiol 21 (1989) 101-108
11. Combs C.A., Katz M.A., Kitzmiller J.L., and Brescia R.J. Experimental preeclampsia produced by chronic constriction of the lower aorta: validation with longitudinal blood pressure measurements in conscious rhesus monkeys. Am J Obstet Gynecol 169 (1993) 215-223
12. Losonczy G., Brown G., and Venuto R.C. Increased peripheral resistance during reduced uterine perfusion pressure hypertension in pregnant rabbits. Am J Med Sci 303 (1992) 233-240
13. Granger J.P., LaMarca B.B., Cockrell K., et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med 122 (2006) 383-392
14. Granger J.P., Alexander B.T., Llinas M.T., Bennett W.A., and Khalil R.A. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Hypertension 38 (2001) 718-722
15. Leite R.S., Brown A.G., and Strauss III J.F. Tumor necrosis factor-alpha suppresses the expression of steroid receptor coactivator-1 and -2: a possible mechanism contributing to changes in steroid hormone responsiveness. FASEB J 18 (2004) 1418-1420
16. Applied Biosystems. Mechanisms of progesterone action in inhibiting prematurity [review]. J Matern Fetal Neonatal Med 19 (2006) 763-772
17. LaMarca B.B., Cockrell K., Sullivan E., Bennett W., and Granger J.P. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 46 (2005) 82-86
18. Alexander B.T., Rinewalt A.N., Cockrell K.L., Massey M.B., Bennett W.A., and Granger J.P. Endothelin type A receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 37 (2001) 485-489
19. LaMarca B.B., Speed J., Fournier L., et al. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of TNF alpha blockade. Hypertension 52 (2008) 1-5
20. Applied Biosystems. User bulletin, no. 2 (1997), Applera Corp, Foster City, CA
21. LaMarca B.B., Gilbert J., and Granger J.P. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension 51 (2008) 982-988
22. Roberts L., LaMarca B., Fournier L., Bain J., Cockrell K., and Gregory J.P. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 47 (2006) 615-618